Cargando…

Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture

In an effort to identify therapeutic intervention strategies for the treatment of COVID-19, we have investigated a selection of FDA-approved small molecules and biologics that are commonly used to treat other human diseases. A investigation into 18 small molecules and 3 biologics was conducted in ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Risner, Kenneth H., Tieu, Katie V., Wang, Yafei, Getz, Michael, Bakovic, Allison, Bhalla, Nishank, Nathan, Steven D., Conway, Daniel E., Macklin, Paul, Narayanan, Aarthi, Alem, Farhang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430595/ https://www.ncbi.nlm.nih.gov/pubmed/32817953 http://dx.doi.org/10.1101/2020.08.12.246389

Ejemplares similares

Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture
por: Bakovic, Allison, et al.
Publicado: (2021)

Inhibitors of Venezuelan Equine Encephalitis Virus Identified Based on Host Interaction Partners of Viral Non-Structural Protein 3
por: Bakovic, Allison, et al.
Publicado: (2021)

Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection
por: Risner, Kenneth, et al.
Publicado: (2019)

Venezuelan Equine Encephalitis Virus nsP3 Phosphorylation Can Be Mediated by IKKβ Kinase Activity and Abrogation of Phosphorylation Inhibits Negative-Strand Synthesis
por: Bakovic, Allison, et al.
Publicado: (2020)

Synthetic Host Defense Peptides Inhibit Venezuelan Equine Encephalitis Virus Replication and the Associated Inflammatory Response
por: Ahmed, Aslaa, et al.
Publicado: (2020)

Inhibition of Venezuelan Equine Encephalitis Virus Using Small Interfering RNAs
por: Haikerwal, Amrita, et al.
Publicado: (2022)

Inhibitors of the Ubiquitin-Mediated Signaling Pathway Exhibit Broad-Spectrum Antiviral Activities against New World Alphaviruses
por: Boghdeh, Niloufar A., et al.
Publicado: (2023)

Application of a Human Blood Brain Barrier Organ-on-a-Chip Model to Evaluate Small Molecule Effectiveness against Venezuelan Equine Encephalitis Virus
por: Boghdeh, Niloufar A., et al.
Publicado: (2022)

Human Antimicrobial Peptides as Therapeutics for Viral Infections
por: Ahmed, Aslaa, et al.
Publicado: (2019)

Mitochondrial-Directed Antioxidant Reduces Microglial-Induced Inflammation in Murine In Vitro Model of TC-83 Infection
por: Keck, Forrest, et al.
Publicado: (2018)

Direct and indirect pro-inflammatory cytokine response resulting from TC-83 infection of glial cells
por: Keck, Forrest, et al.
Publicado: (2018)

Interactions of Equine Viruses with the Host Kinase Machinery and Implications for One Health and Human Disease
por: Anderson, Carol, et al.
Publicado: (2023)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Proteomic Discovery of VEEV E2-Host Partner Interactions Identifies GRP78 Inhibitor HA15 as a Potential Therapeutic for Alphavirus Infections
por: Barrera, Michael D., et al.
Publicado: (2021)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response
por: Oktay, Esra, et al.
Publicado: (2023)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

The transcriptional landscape of Venezuelan equine encephalitis virus (TC-83) infection
por: Yao, Zhiyuan, et al.
Publicado: (2021)

Immunologic impact of maraviroc in clinical practice of a university hospital
por: Paniagua, S Plata, et al.
Publicado: (2010)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Maraviroc: a review of its use in HIV infection and beyond
por: Woollard, Shawna M, et al.
Publicado: (2015)

Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock
por: Liu, Fu-Chao, et al.
Publicado: (2016)

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
por: Pujari, Sanjay, et al.
Publicado: (2018)

Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals
por: Kawana-Tachikawa, Ai, et al.
Publicado: (2014)

HIV entry blocked by maraviroc can cause an overestimation of viral load
por: Sloan, RD, et al.
Publicado: (2010)

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient
por: Bregigeon, Sylvie, et al.
Publicado: (2010)

Role of maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced
por: Cipriani, S, et al.
Publicado: (2012)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients
por: Piconi, Stefania, et al.
Publicado: (2016)

Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity
por: Legnani, L., et al.
Publicado: (2016)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
por: Ilomuanya, Margaret O., et al.
Publicado: (2020)

A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics
por: Karris, Maile Y., et al.
Publicado: (2016)

Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days
por: Haymond, Amanda, et al.
Publicado: (2021)

Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
por: Poveda, Eva, et al.
Publicado: (2010)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc
por: Rodriguez, Christophe, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gfentn6c4k1va85kbkqfsl76na